Amneal closes acquisition of Kashiv BioSciences to build biosimilars platform
Amneal paid $375 million in cash plus 28.9 million shares, with up to $350 million in milestone payments and royalties tied to the deal.
SEC filing
Latest
10 stories
Monday, September 14
Friday, August 21
Amneal's generic isotretinoin gets labeling supplement approved by FDA
Friday, August 14
Amneal clears five FDA supplements: REMS update on buprenorphine/naloxone leads week
Monday, August 10
Wednesday, August 5
Amneal wins two labeling supplement approvals for extended-release Lamotrigine ANDA
Monday, August 3
Amneal repriced term loans, cutting interest rate margin by 50 basis points
The company estimates roughly $12 million in annual cash interest savings from the amendment, which does not change the 2032 maturity date.
SEC filing
Thursday, July 30
Amneal raises 2026 guidance again, reprices term loan, moves ahead on Kashiv deal
The company's second raise of full-year guidance this year came alongside a $2.084 billion term loan repricing and plans for $350 million in new debt to help fund the pending Kashiv BioSciences acquisition.
SEC filing
Amneal wins FDA supplement approval for mycophenolate mofetil oral suspension REMS update
Thursday, July 23
Amneal adds metformin labeling approval alongside bosentan updates
Thursday, July 9
FDA approves Amneal's sodium bicarbonate injection NDA220790
The new drug application for an intravenous sodium bicarbonate solution received original approval as a Type 5 new formulation or new manufacturer submission.
Drugs@FDA